What Do Analysts Have to Say About Gilead Sciences (GILD) Post Earnings?

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results on February 10, reporting a strong year marked by the continued growth of Biktarvy and Descovy, along with the successful launch of Yeztugo, the world’s first twice-yearly HIV prevention therapy in the country. Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs Gilead Sciences, Inc. ( ...